Year: 2025
Type: article
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is characterised by an immunosuppressive tumour microenvironment (TME), where M2-type macrophages promote tumour growth and limit therapeutic efficacy. Reprogramming these M2 macrophages into pro-inflammatory, antitumour M1 phenotypes represents a potential immunomodulatory strategy to enhance immune-mediated tumour clearance. Preclinical studies suggest that combining macrophage reprogramming with chemotherapy or stromal-targeting agents can increase cytotoxic T cell infiltration and reduce tumour progression.
Source: Immuno-Oncology Technology
Authors: M. Alam, R-J. Lamers, R. Choudhury
Language: English
Topic: Immune cells in cancer
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,340
OpenAlex ID: W7117307170
FWCI:
Cites:
Cited by:
Related to: